Abstract
Typhoid fever, an infection with potentially life threatening complications, is responsible for 11 to 21 million illness episodes and 145,000 to 161,000 deaths each year globally. India is a high burden country and also faces the challenge of antimicrobial resistance, which further narrows treatment options. This review analyzes the need for typhoid vaccination in India, and appraises the evidence on efficacy, immunogenicity and cost-effectiveness of currently available typhoid vaccines. In 2018, WHO prequalified the first typhoid conjugate vaccine Vi-TT and recommended it for children aged 6–23 months, along with measles vaccine at 9 or 15 months of age through the expanded programme on immunization. With the high endemicity of typhoid in India and the proven cost-effectiveness of the conjugate vaccine, a roll-out of typhoid vaccine should be considered at the earliest.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
World Health Organization. Progress on drinking water, sanitation and hygiene: 2017 update and SDG baselines. Available from: http://www.who.int/water_sanitation_health/publications/jmp-2017/en/. Accessed June 29, 2018.
Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: A systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2:e570–80.
Antillón M, Warren JL, Crawford FW, Weinberger DM, Kurum E, Pak GD, et al. The burden of typhoid fever in low- and middle-income countries: A meta-regression approach. PLoS Negl Trop Dis. 2017;11:e0005376.
John J, Van Aart CJ, Grassly NC. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis. PLoS Negl Trop Dis. 2016;10:e0004616.
Ochiai RL. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86:260–8.
Mogasale V, Desai SN, Mogasale VV, Park JK, Ochiai RL, Wierzba TF. Case fatality rate and length of hospital stay among patients with typhoid intestinal perforation in developing countries: A systematic literature review. PLoS One. 2014;9:e93784.
Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet. 2015;47:632–9.
Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio. 2018;9:e00105–18.
Steele AD, Hay Burgess DC, Diaz Z, Carey ME, Zaidi AKM. Challenges and opportunities for typhoid fever control: A call for coordinated action. Clin Infect Dis. 2016;62:S4–8.
Typhoid vaccines: WHO position paper - August 2000. Wkly Epidemiol Recd. 2000;75:257–64.
Typhoid vaccines: WHO position paper - February 2008. Wkly Epidemiol Recd. 2008;83:49–59.
World Health Organisation. Background Paper to SAGE on Typhoid Vaccine Policy Recommendations, 2017. Available from http://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B.pdf. Accessed August 12, 2018.
Typhoid vaccines: WHO position paper-March 2018. Wkly Epidemiol Recd. 2018; 93:153–72.
World Health Organization. The immunological basis for immunization series: module 20: salmonella enterica serovar Typhi (typhoid) vaccines. 2011. Available from: http://www.who.int/iris/handle/10665/44752. Accessed August 12, 2018.
Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390:2472–80.
Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, et al. Efficacy and safety of Vi-tetanus toxoid conjugated typhoid vaccine (PedaTyphTM) in Indian children: School based cluster randomized study. Hum Vaccines Immunother. 2016;12:939–45.
Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: A multicenter, 2-cohort, open-label, doubleblind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61:393–402.
Voysey M, Pollard AJ. Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV). Clin Infect Dis. 2018;67:18–24.
Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35:3506–14.
Lo NC, Gupta R, Stanaway JD, Garrett DO, Bogoch II, Luby SP, et al. Comparison of strategies and incidence thresholds for vi conjugate vaccines against typhoid fever: A cost-effectiveness modeling study. J Infect Dis. 2018;218:S232–42.
Andrews JR, Baker S, Marks F, Alsan M, Garrett D, Gellin BG, et al. Typhoid conjugate vaccines: A new tool in the fight against antimicrobial resistance. Lancet Infect Dis. 2019;19:e26–30.
Balasubramanian S, Shah A, Pemde HK, Chatterjee P, Shivananda S, Guduru VK, et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines And Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years. Indian Pediatr. 2018; 55:1066–74.
GAVI 2018. New Typhoid Vaccine to Receive GAVI Support. Available from: https://www.gavi.org/library/news/statements/2018/new-typhoid-vaccine-to-receive-gavi-support/. Accessed August 12, 2018.
World Health Organizationý. Typbar TCV® from Bharat Biotech, world’s first typhoid conjugate vaccine prequalified by WHO. 2018. Available from: http://www.who.int/medicines/news/2017/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf. Accessed August 12, 2018.
NSSEFI Collaborators, John J, Bavdekar A, Rongsen-Chandola T, Dutta S, Kang G. Estimating the incidence of enteric fever in children in India: A multi-site, active fever surveillance of pediatric cohorts. BMC Public Health. 2018;18:594.
Meiring JE, Gibani M, Basnyat B, Bentsi-Enchill AD, Clemens J, Darton TC, et al. The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK. Vaccine. 2017;35:5081–8.
Coalition against typhoid. Navi Mumbai Municipal Corporation launches the world’s first public-sector typhoid conjugate vaccine campaign. 2018. Available from: http://www.coalitionagainsttyphoid.org/navi-mumbai-municipal-corporation-launches-the-worlds-first-public-sector-typhoid-conjugate-vaccine-campaign/. Accessed December 22, 2018.
Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018;CD001261.
Klugman KP. Usefulness of the serial measurement of Vi antibodies. Clin Infect Dis. 2018;67:25–6.
Lin FYC, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344:1263–9.
Lanh MN, Van Bay P, Ho VA, Thanh TC, Lin FYC, Bryla DA, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med. 2003;349:1390–1.
Funding
Funding: None; Competing interests: None stated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Srinivasan, M., Sindhu, K.N., John, J. et al. Opportunities for Typhoid Vaccination in India. Indian Pediatr 56, 453–458 (2019). https://doi.org/10.1007/s13312-019-1566-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-019-1566-7